JG
INDV icon

Jain Global’s Indivior Pharmaceuticals INDV Stock Holding History

Jain Global’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-92,769
Closed -$2.24M – 1356
2025
Q3 		$2.24M Buy
+92,769
New +$1.94M 0.01% 513
2025
Q2 		– Sell
-146,507
Closed -$1.4M – 1392
2025
Q1 		$1.4M Buy
+146,507
New +$1.54M 0.02% 404

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jain Global's INDV Position: Q4 2025 in Review

Jain Global sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 92,769 shares — an estimated $2.24M sold.

Jain Global first reported a position in INDV in Q1 2025 and held it in 2 quarters. The position peaked at $2.24M in Q3 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

  • Jain Global reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jain Global sold 92,769 Indivior Pharmaceuticals shares in Q4 2025, an estimated $2.24M.
  • Jain Global first reported a position in Indivior Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Jain Global's Indivior Pharmaceuticals position peaked at $2.24M in Q3 2025.
  • 259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on Jain Global's 13F filing for Q4 2025, filed 17 Feb 2026.